['psoriasis']
['ustekinumab', 'guselkumab', 'placebo for ustekinumab', 'placebo for guselkumab']

        Inclusion Criteria:

          -  Have a diagnosis of plaque-type psoriasis (with or without psoriatic arthritis for at
             least 6 months before the first administration of study drug

          -  Have a Psoriasis Area and Severity Index (PASI) greater than or equal to (>=) 12 at
             Screening and at Baseline

          -  Have an Investigator's Global Assessment (IGA) >=3 at Screening and at Baseline

          -  Have an involved body surface area (BSA) >= 10 percent (%) at Screening and at
             Baseline

          -  Be a candidate for phototherapy or systemic treatment for psoriasis (either naïve or
             history of previous treatment)

        Exclusion Criteria:

          -  Has a history or current signs or symptoms of severe, progressive, or uncontrolled
             renal, hepatic, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic,
             hematologic, rheumatologic, psychiatric, or metabolic disturbances

          -  Has unstable cardiovascular disease, defined as a recent clinical deterioration
             (example [eg], unstable angina, rapid atrial fibrillation) in the last 3 months or a
             cardiac hospitalization within the last 3 months

          -  Currently has a malignancy or has a history of malignancy within 5 years before
             Screening (with the exception of a nonmelanoma skin cancer that has been adequately
             treated with no evidence of recurrence for at least 3 months before the first study
             drug administration, or cervical carcinoma in situ that has been treated with no
             evidence of recurrence for at least 3 months before the first study drug
             administration)

          -  Has previously received guselkumab or ustekinumab
      